文献速递胸部肿瘤

二代奥希替尼耐药机制及预后意义的NGS探索

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
PubMed 文献 · Eur J Cancer · 2021-03-18

该研究纳入34例EGFR突变晚期肺腺癌患者,对比奥希替尼治疗前后肿瘤组织的靶向NGS结果,探索二线奥希替尼的耐药机制。结果显示T790M丢失与更短的无进展生存期相关,MET扩增进一步加剧早期耐药,部分患者出现小细胞癌或鳞癌转化。

要点

  • T790M丢失者奥希替尼PFS显著短于T790M保留者(5.36 vs 13.81个月,p=0.009)。
  • T790M丢失且MET扩增者PFS更差(2.10 vs 6.35个月,p=0.01)。
  • 耐药时可见小细胞癌转化、鳞癌转化及KRAS/PIK3CA突变、RET融合等。

核心结论

  • T790M丢失与奥希替尼早期耐药相关,MET扩增可进一步加剧这一不良预后。

研究设计与样本

  • 研究纳入34例EGFR突变晚期肺腺癌患者,在奥希替尼进展时对活检肿瘤组织行靶向NGS,并与奥希替尼开始前的存档肿瘤组织NGS结果进行对比。

主要发现

  • 3例患者肿瘤转化为小细胞癌,2例转化为鳞状细胞癌。
  • 其余29例中,7例(24.1%)维持T790M突变,其中4例(13.8%)获得C797S突变,1例出现MET扩增。
  • 22例(75.9%)T790M丢失,鉴定出KRAS突变、PIK3CA突变和RET融合等多种新发变异,MET扩增(n=4,18.2%)为最常见变异。
  • T790M丢失者奥希替尼PFS短于T790M维持者(5.36 vs 13.81个月,p=0.009)。
  • T790M丢失患者中,MET扩增者PFS更差(2.10 vs 6.35个月,p=0.01)。

临床怎么用

  • 奥希替尼进展时建议再次活检行NGS,以明确T790M状态及MET扩增等耐药机制。
  • T790M丢失尤其合并MET扩增提示早期耐药,可考虑更密切监测或临床试验。
  • 发现小细胞癌或鳞癌转化者应按相应组织学类型调整治疗策略。

局限性

  • 样本量较小(34例),结论需更大样本验证。
  • 作者指出需进一步研究以充分理解每种耐药机制的意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although osimertinib overcomes the T790M mutation acquired after traditional epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitor (TKI) treatment, resistance to osimertinib eventually occurs. We explored resistance mechanisms of second-line osimertinib and their clinical implications by comparing next-generation sequencing (NGS) results before and after resistance acquisition. METHODS: We enrolled 34 patients with advanced EGFR-mutant adenocarcinoma whose biopsied tumour tissues were subjected to targeted NGS at the time of progression on osimertinib. For comparison, NGS was also performed on archived tumour tissues from each patient excised before osimertinib initiation. RESULTS: The tumours of three patients' were observed to have transformed to small-cell carcinoma and those of two patients to squamous cell carcinoma. Among the remaining 29 patients, T790M mutations were maintained in seven patients (24.1%), including four patients (13.8%) acquiring C797S mutations and one with MET amplification. Among the 22 patients (75.9%) with T790M loss, a variety of novel mutations were identified, including KRAS mutations, PIK3CA mutations, and RET fusion, but MET amplifications (n = 4, 18.2%) were most frequently identified variations. Progression-free survival (PFS) on osimertinib was shorter among patients with T790M loss than among those who maintained T790M (5.36 versus 13.81 months, p = 0.009), and MET-amplified patients were found to have much worse PFS among patients with T790M loss (2.10 versus 6.35 months, p = 0.01). CONCLUSIONS: Loss of the T790M mutation was associated with early resistance to osimertinib, and this was exacerbated by MET amplification. Further work is needed to fully understand the implications of each resistance mechanism.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee K, Kim D, Yoon S, et al. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Eur J Cancer. 2021. PMID: 33744716. doi:10.1016/j.ejca.2021.01.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。